ReviewThrombosis research2010
Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.
Review in Thrombosis research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- Exercise, Neuroprotective Exerkines, and Parkinson's Disease: A Narrative Review.Biomolecules · 2024Review
- Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies.Current treatment options in oncology · 2024Review
- Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis.Scientific reports · 2022Article
- Suggestions on leading an academic research laboratory group.Open life sciences · 2022Article
- Article
- Dissecting molecular details and functional effects of the high-affinity copper binding site in plasminogen activator Inhibitor-1.Protein science : a publication of the Protein Society · 2021Article
- Identification of a PAI-1-binding site within an intrinsically disordered region of vitronectin.Protein science : a publication of the Protein Society · 2020Article
- Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer.Molecular cancer research : MCR · 2019Article
- Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.Journal of cellular and molecular medicine · 2019Article
- Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.Current drug targets · 2019Review
- The inhibitory effect of oridonin on colon cancer was mediated by deactivation of TGF-β1/Smads-PAI-1 signaling pathway in vitro and vivo.OncoTargets and therapy · 2019Article
- Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer.Cell reports · 2018Article
- CompoundExperimental and therapeutic medicine · 2018Article
- Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy.Oncotarget · 2016Article
- The effect of acute and long-term physical activity on extracellular matrix and serglycin in human skeletal muscle.Physiological reports · 2015Article
- Bilateral pulmonary embolism in twins with PAI-1 4G/5G gene polymorphism: a case report.Wiener klinische Wochenschrift · 2014Article
- Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.BMJ open · 2013Article
- Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.Journal of experimental & clinical cancer research : CR · 2013Article
- Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion.Leukemia & lymphoma · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In hemostasis, the serine protease inhibitor (serpin) plasminogen activator inhibitor-1 (PAI-1) functions to stabilize clots via inhibition of tissue plasminogen activator (tPA) with subsequent inhibition of fibrinolysis. In tissues, PAI-1 functions to inhibit extracellular matrix degradation via inhibition of urokinase plasminogen activator (uPA). Elevated levels of PAI-1 in the vasculature and in tissues have long been known to be associated with thrombosis and fibrosis, respectively. However, there is emerging evidence that PAI-1 may participate in the pathophysiology of a number of diseases such as atherosclerosis, restenosis, and cancer. In many of these disease states, the canonical view of PAI-1 as an inhibitor of tPA and uPA cannot fully account for a mechanism whereby PAI-1 contributes to the disease. In these cases, one must consider recent data, which indicates PAI-1 can directly promote pro-proliferative and anti-apoptotic signaling in a variety of cell types. Given the wide variety of inflammatory, hormonal, and metabolic signals that increase PAI-1 expression, it is important to consider mechanisms by which PAI-1 can directly participate in disease etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.